International Journal of Clinical Oncology (2020) 25:1744–1745
https://doi.org/10.1007/s10147-020-01752-4

CORRECTION

Correction to: Results of a phase II trial for high-risk neuroblastoma treatment protocol JN-H-07: a report from the Japan Childhood Cancer Group Neuroblastoma Committee (JNBSG)

Tomoro Hishiki[1,2] · Kimikazu Matsumoto[1] · Miki Ohira[3] · Takehiko Kamijo[3] · Hiroyuki Shichino[4] · Tatsuo Kuroda[5] · Akihiro Yoneda[6] · Toshinori Soejima[7] · Atsuko Nakazawa[8] · Tetsuya Takimoto[9] · Isao Yokota[10] · Satoshi Teramukai[10] · Hideto Takahashi[11] · Takashi Fukushima[12] · Takashi Kaneko[13] · Junichi Hara[14] · Michio Kaneko[15] · Hitoshi Ikeda[16] · Tatsuro Tajiri[17] · Akira Nakagawara[18] · For the Japan Childhood Cancer Group Neuroblastoma Committee (JNBSG)

Published online: 4 August 2020

Correction to:
International Journal of Clinical Oncology (2018) 23:965–973
https://doi.org/10.1007/s10147-018-1281-8

In the October 2018 issue of International Journal of Clinical Oncology, in the article titled "Results of a phase II trial for high-risk neuroblastoma treatment protocol JN-H-07: a report from the Japan Childhood Cancer Group Neuroblastoma Committee (JNBSG)" (volume 23, pages 965–973; doi: https://doi.org/10.1007/s10147-018-1281-8.), by Hishiki T et al., there was a printing error in Figure 1. In the description for the schedule of the induction regime 05A1 and 05A3, the arrow that shows the day of pirarubicin administration was intended to indicate day 3, but in error had been published with the arrows indicating purarubicin administration on day 2.

We sincerely apologize for this error in the schedule of the regime.

The original article can be found online at https://doi.org/10.1007/s10147-018-1281-8.

✉ Tomoro Hishiki
tomoro.hishiki@gmail.com

1 Children's Cancer Center, National Center for Child Health and Development, 2-10-1 Okura, Setagaya-ku, Tokyo 157-8535, Japan

2 Pediatric Surgical Oncology, National Cancer Center Hospital, Tokyo, Japan

3 Research Institute for Clinical Oncology, Saitama Cancer Center, Saitama, Japan

4 Pediatrics, National Center for Global Health and Medicine, Tokyo, Japan

5 Pediatric Surgery, Keio University School of Medicine, Tokyo, Japan

6 Pediatric Surgery, Osaka City General Hospital, Osaka, Japan

7 Kobe Proton Center, Kobe, Japan

8 Pathology, National Center for Child Health and Development, Tokyo, Japan

9 Clinical Epidemiology Research Center for Pediatric Cancer, National Center for Child Health and Development, Tokyo, Japan

10 Biostatistics, Kyoto Prefectural University of Medicine, Kyoto, Japan

11 National Institute of Public Health, Saitama, Japan

12 Pediatrics, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan

13 Hematology and Oncology, Tokyo Metropolitan Children's Medical Center, Tokyo, Japan

14 Pediatric Hematology and Oncology, Osaka City General Hospital, Osaka, Japan

15 Ibaraki Prefectural Association of Health Evaluation and Promotion, Mito, Japan

16 Pediatric Surgery, Dokkyo Medical University Koshigaya Hospital, Koshigaya, Japan

17 Pediatric Surgery, Kyoto Prefectural University of Medicine, Kyoto, Japan

18 Saga Medical Center, KOSEIKAN Hospital, Saga, Japan



MEC is substituted with a 5th cycle of 05A3 in patients with *MYCN* non-amplified stage 3 neuroblastoma (unfavorable histology)

Induction chemotherapy

05A1

Cycle 1		day 1	2	3	4	5
Cyclophosphamide	1200 mg/m²/day	↓				
Vincristine	1.5 mg/m²/day	↓				
Pirarubicin	40 mg/m²/day			↓		
Cisplatin	20 mg/m²/day	↓	↓	↓	↓	↓

05A3

Cycle 2,3,4,5		day 1	2	3	4	5
Cyclophosphamide	1200 mg/m²/day	↓	↓			
Vincristine	1.5 mg/m²/day	↓				
Pirarubicin	40 mg/m²/day			↓		
Cisplatin	20 mg/m²/day	↓	↓	↓	↓	↓

Consolidation chemotherapy with autologous PBSC transplantation

07MEC

		day -9	-8	-7	-6	-5	-4	-3	-2	-1	0
Melphalan	100 mg/m²/day					↓	↓				
Etoposide	200 mg/m²/day			↓	↓	↓	↓				
Carboplatin	400 mg/m²/day			↓	↓	↓	↓				

PBSC infusion

modified April 2009 in response to occurrence of capillary leak syndrome events

09MEC

		day -9	-8	-7	-6	-5	-4	-3	-2	-1	0
Melphalan	100 mg/m²/day	↓	↓								
Etoposide	200 mg/m²/day			↓	↓	↓	↓				
Carboplatin	400 mg/m²/day			↓	↓	↓	↓				

PBSC infusion

Radiotherapy

Radiotherapy

Fractionated radiotherapy (19.8 Gy) given in eleven equal fractions (1.8 Gy per fraction). Additional boost dose 10.8 Gy for macroscopic residual diseases in six equal fractions. Metastatic bone lesions with ^{123}I-MIBG uptake before MEC is subjected to 19.8 Gy fractionated radiotherapy as described above.